SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy

•SDF-1 is enriched at bone marrow (BM) metastasis sites from solid tumors and MM•Ola-PEG binds and neutralizes SDF-1 in vivo•SDF-1 neutralization within the BM niche prevents or delays bone metastases

SummaryBone marrow (BM) metastasis remains one of the main causes of death associated with solid tumors as well as multiple myeloma (MM). Targeting the BM niche to prevent or modulate metastasis has not been successful to date. Here, we show that stromal cell-derived factor-1 (SDF-1/CXCL12) is highly expressed in active MM, as well as in BM sites of tumor metastasis and report on the discovery of the high-affinity anti-SDF-1 PEGylated mirror-image l-oligonucleotide (olaptesed-pegol). In vivo confocal imaging showed that SDF-1 levels are increased within MM cell-colonized BM areas. Using in vivo murine and xenograft mouse models, we document that in vivo SDF-1 neutralization within BM niches leads to a microenvironment that is less receptive for MM cells and reduces MM cell homing and growth, thereby inhibiting MM disease progression. Targeting of SDF-1 represents a valid strategy for preventing or disrupting colonization of the BM by MM cells.

Graphical AbstractFigure optionsDownload full-size imageDownload as PowerPoint slide